A mouse study found that the drug tirzepatide significantly reduces body weight and adipose tissue, while also shrinking obesity-linked breast tumors. Researchers at the University of Michigan noted that tirzepatide, a dual GLP-1/GIP medication, could serve as a promising therapy for reducing cancer risk in obese individuals. They emphasized that existing evidence shows obesity adversely affects breast cancer outcomes, and that weight loss generally leads to improvements. The study suggests new anti-obesity drugs may help tackle the dual issues of obesity and associated cancer growth.
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model.
Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes.
Mice on tirzepatide shed major pounds and, in the process, their breast tumors shrank—early evidence that weight-loss drugs might also tame obesity-driven cancers.
Existing research has shown that having obesity can lead to worse breast cancer outcomes compared to those who do not have obesity, and weight loss can improve outcomes.
Collection
[
|
...
]